Ongoing trials:

Principal Investigator: “ALXN-MG-501, Long-Term, Observational, Registry of Patients with Generalized Myasthenia Gravis Who Have Received Treatment with Complement C5 Inhibition Therapies”

Principal Investigator: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older with Active Idiopathic Inflammatory Myopathy

Principal Investigator: A Phase 4, Open label, Prospective, Single Group, Multicenter Study to Evaluate the Clinical Outcomes of Egfartigimod PH20 SC in Adult Participants with New Onset Generalized Myasthenia Gravis

Principal Investigator: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Mild to Severe Generalized Myasthenia Gravis 

Principal Investigator: A Global Real-World Study to Assess HyQvia Use and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Switching to HyQvia

Principal Investigator: A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CDP)

 Principal Investigator: A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients with Multifocal Motor Neuropathy

Completed trials:

Principal Investigator: DDF, “IVIG in Dysimmune Inflammatory Neuropathy (DIN) with/without Diabetes Mellitus (DM)”

Principal Investigator: ADHERE: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)

Principal Investigator: ADHERE+: Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

 Principal Investigator: MG 0017: An open-label study to evaluate the safety, tolerability, and efficacy of subcutaneous zilucoplan in participants with generalized myasthenia gravis who were previously receiving intravenous complement component 5 inhibitors